Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments

Cancer Letters

Volumn 345, Issue 1, 2014, Pages 48-55

  Yokoi, Kenji ^a,b   Tanei, Tomonori ^a   Godin, Biana ^a   van de Ven, Anne L ^a   Hanibuchi, Masaki ^b   Matsunoki, Aika ^b   Alexander, Jenolyn ^a   Ferrari, Mauro ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biomarker; EPR effect; Nanotherapeutics; PLD; Transport oncophysics

Indexed keywords

BIOMARKER; EPR EFFECT; NANOTHERAPEUTICS; PLD; TRANSPORT ONCOPHYSICS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BRAIN NEOPLASMS; CAPILLARY PERMEABILITY; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; LIVER NEOPLASMS, EXPERIMENTAL; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; POLYETHYLENE GLYCOLS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893793833     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.11.015     Document Type: Article

References (37)

1. Ferrari M. Nanogeometry: beyond drug delivery. Nat. Nanotechnol. 2008, 3:131-132.
2. Wang A.Z., Langer R., Farokhzad O.C. Nanoparticle delivery of cancer drugs. Annu. Rev. Med. 2012, 63:185-198.
3. Duggan S.T., Keating G.M. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma. Drugs 2011, 71:2531-2558.
4. Chauhan V.P., Stylianopoulos T., Boucher Y., Jain R.K. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu. Rev. Chem. Biomol. Eng. 2012, 2:281-298.
5. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control Release 2000, 65:271-284.
6. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008, 7:771-782.
7. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 2010, 7:653-664.
8. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 2001, 19:3312-3322.
9. O'Brien M.E., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., Catane R., Kieback D.G., Tomczak P., Ackland S.P., Orlandi F., Mellars L., Alland L., Tendler C. CAELYX breast cancer study group, reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 2004, 15:440-449.
10. Northfelt D.W., Dezube B.J., Thommes J.A., Miller B.J., Fischl M.A., Friedman-Kien A., Kaplan L.D., Du Mond C., Mamelok R.D., Henry D.H. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J. Clin. Oncol. 1998, 16:2445-2451.
11. Sanhai W.R., Sakamoto J.H., Canady R., Ferrari M. Seven challenges for nanomedicine. Nat. Nanotechnol. 2008, 3:242-244.
12. Baluk P., Morikawa S., Haskell A., Mancuso M., McDonald D.M. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 2003, 163:1801-1815.
13. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J. Control Release 2009, 164:138-144.
14. Amar S., Roy V., Perez E.A. Treatment of metastatic breast cancer: looking towards the future. Breast Cancer Res. Treat. 2009, 114:413-422.
15. Lièvre A., Bachet J.B., Boige V., Cayre A., Le Corre D., Buc E., Ychou M., Bouché O., Landi B., Louvet C., André T., Bibeau F., Diebold M.D., Rougier P., Ducreux M., Tomasic G., Emile J.F., Penault-Llorca F., Laurent-Puig P. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 2008, 26:374-379.
16. Corless C.L., Barnett C.M., Heinrich M.C. Gastrointestinal stromal tumours: origin and molecular oncology. Nat. Rev. Cancer 2011, 11:865-878.
17. Brantley E.C., Guo L., Zhang C., Lin Q., Yokoi K., Langley R.R., Kruzel E., Maya M., Kim S.W., Kim S.J., Fan D., Fidler I.J. Nitric oxide-mediated tumoricidal activity of murine microglial cells. Transl. Oncol. 2010, 3:380-388.
18. Shinohara H., Killion J.J., Bucana C.D., Yano S., Fidler I.J. Oral administration of the immunomodulator JBT-3002 induces endogenous interleukin 15 in intestinal macrophages for protection against irinotecan-mediated destruction of intestinal epithelium. Clin. Cancer Res. 1999, 5:2148-2156.
19. Yokoi K., Godin B., Oborn C.J., Alexander J.F., Liu X., Fidler I.J., Ferrari M. Porous silicon nanocarriers for dual targeting tumor associated endothelial cells and macrophages in stroma of orthotopic human pancreatic cancers. Cancer Lett. 2013, 334:319-327.
20. Ozawa S., Shinohara H., Kanayama H.O., Bruns C.J., Bucana C.D., Ellis L.M., Davis D.W., Fidler I.J. Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha. Neoplasia 2001, 3:154-164.
21. Low J.A., Johnson M.D., Bone E.A., Dickson R.B. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin. Cancer Res. 1996, 2:1207-1214.
22. Ren Y., Cheung H.W., von Maltzhan G., Agrawal A., Cowley G.S., Weir B.A., Boehm J.S., Tamayo P., Karst A.M., Liu J.F., Hirsch M.S., Mesirov J.P., Drapkin R., Root D.E., Lo J., Fogal V., Ruoslahti E., Hahn W.C., Bhatia S.N. Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci. Transl. Med. 2012, 4:47-112.
23. Diop-Frimpong B., Chauhan V.P., Krane S., Boucher Y., Jain R.K. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc. Natl. Acad. Sci. USA 2011, 108:2909-2914.
24. Vaage J., Donovan D., Uster P., Working P. Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. Br. J. Cancer 1997, 75:482-486.
25. Erikson A., Tufto I., Bjønnum A.B., Bruland Ø.S., Davies CdeL The impact of enzymatic degradation on the uptake of differently sized therapeutic molecules. Anticancer Res. 2008, 28:3557-3566.
26. Cruz-Monserrate Z., Abd-Elgaliel W.R., Grote T., Deng D., Ji B., Arumugam T., Wang H., Tung C.H., Logsdon C.D. Detection of pancreatic cancer tumours and precursor lesions by cathepsin E activity in mouse models. Gut 2012, 61:1315-1322.
27. van de Ven A.L., Wu M., Lowengrub J., McDougall S.R., Chaplain M.A., Cristini V., Ferrari M., Frieboes H.B. Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. AIP Adv. 2012, 2:11208.
28. van de Ven A.L., Kim P., Haley O., Fakhoury J.R., Adriani G., Schmulen J., Moloney P., Hussain F., Ferrari M., Liu X., Yun S.H., Decuzzi P. Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J. Control Release 2012, 158:148-155.
29. Bonoiu A., Mahajan S.D., Ye L., Kumar R., Ding H., Yong K.T., Roy I., Aalinkeel R., Nair B., Reynolds J.L., Sykes D.E., Imperiale M.A., Bergey E.J., Schwartz S.A., Prasad P.N. MMP-9 gene silencing by a quantum dot-siRNA nanoplex delivery to maintain the integrity of the blood brain barrier. Brain Res. 2009, 1282:142-155.
30. Fujimura M., Gasche Y., Morita-Fujimura Y., Massengale J., Kawase M., Chan P.H. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res. 1999, 842:92-100.
31. Moulton K.S., Olsen B.R., Sonn S., Fukai N., Zurakowski D., Zeng X. Loss of collagen XVIII enhances neovascularization and vascular permeability in atherosclerosis. Circulation 2004, 110:1330-1336.
32. Tang X. Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. Cancer Lett. 2013, 332:3-10.
33. Ferrari M. Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends. Biotechnol. 2010, 28:181-188.
34. Michor F., Liphardt J., Ferrari M., Widom J. What does physics have to do with cancer?. Nat. Rev. Cancer 2011, 11:657-670.
35. Malemud C.J. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci. 2006, 11:1696-1701.
36. Reichel C.A., Rehberg M., Bihari P., Moser C.M., Linder S., Khandoga A., Krombach F. Gelatinases mediate neutrophil recruitment in vivo: evidence for stimulus specificity and a critical role in collagen IV remodeling. J. Leukoc. Biol. 2008, 83:864-874.
37. Hornebeck W., Lambert E., Petitfrère E., Bernard P. Beneficial and detrimental influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progression. Biochimie 2005, 87:377-383.